148 related articles for article (PubMed ID: 35177646)
1. The significance of ErbB2/3 in the conversion of induced pluripotent stem cells into cancer stem cells.
Hassan G; Zahra MH; Seno A; Seno M
Sci Rep; 2022 Feb; 12(1):2711. PubMed ID: 35177646
[TBL] [Abstract][Full Text] [Related]
2. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
3. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Awasthi S; Hamburger AW
J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179
[TBL] [Abstract][Full Text] [Related]
4. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
5. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling.
Wang L; Schulz TC; Sherrer ES; Dauphin DS; Shin S; Nelson AM; Ware CB; Zhan M; Song CZ; Chen X; Brimble SN; McLean A; Galeano MJ; Uhl EW; D'Amour KA; Chesnut JD; Rao MS; Blau CA; Robins AJ
Blood; 2007 Dec; 110(12):4111-9. PubMed ID: 17761519
[TBL] [Abstract][Full Text] [Related]
6. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of PI3Kγ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells.
Xu Y; Afify SM; Du J; Liu B; Hassan G; Wang Q; Li H; Liu Y; Fu X; Zhu Z; Chen L; Seno M
Sci Rep; 2022 Jan; 12(1):347. PubMed ID: 35013447
[TBL] [Abstract][Full Text] [Related]
8. A novel model of liver cancer stem cells developed from induced pluripotent stem cells.
Afify SM; Sanchez Calle A; Hassan G; Kumon K; Nawara HM; Zahra MH; Mansour HM; Khayrani AC; Alam MJ; Du J; Seno A; Iwasaki Y; Seno M
Br J Cancer; 2020 Apr; 122(9):1378-1390. PubMed ID: 32203212
[TBL] [Abstract][Full Text] [Related]
9. Signaling Inhibitors Accelerate the Conversion of mouse iPS Cells into Cancer Stem Cells in the Tumor Microenvironment.
Du J; Xu Y; Sasada S; Oo AKK; Hassan G; Mahmud H; Khayrani AC; Alam MJ; Kumon K; Uesaki R; Afify SM; Mansour HM; Nair N; Zahra MH; Seno A; Okada N; Chen L; Yan T; Seno M
Sci Rep; 2020 Jun; 10(1):9955. PubMed ID: 32572057
[TBL] [Abstract][Full Text] [Related]
10. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Begum A; Ewachiw T; Jung C; Huang A; Norberg KJ; Marchionni L; McMillan R; Penchev V; Rajeshkumar NV; Maitra A; Wood L; Wang C; Wolfgang C; DeJesus-Acosta A; Laheru D; Shapiro IM; Padval M; Pachter JA; Weaver DT; Rasheed ZA; Matsui W
PLoS One; 2017; 12(7):e0180181. PubMed ID: 28692661
[TBL] [Abstract][Full Text] [Related]
11. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ
J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028
[TBL] [Abstract][Full Text] [Related]
12. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
13. RNA Polymerase II-Associated Factor 1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions With PHF5A and DDX3.
Karmakar S; Rauth S; Nallasamy P; Perumal N; Nimmakayala RK; Leon F; Gupta R; Barkeer S; Venkata RC; Raman V; Rachagani S; Ponnusamy MP; Batra SK
Gastroenterology; 2020 Nov; 159(5):1898-1915.e6. PubMed ID: 32781084
[TBL] [Abstract][Full Text] [Related]
14. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
Wang S; Huang J; Lyu H; Lee CK; Tan J; Wang J; Liu B
Cell Death Dis; 2013 Mar; 4(3):e556. PubMed ID: 23519125
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
16. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.
Lund CV; Popkov M; Magnenat L; Barbas CF
Mol Cell Biol; 2005 Oct; 25(20):9082-91. PubMed ID: 16199884
[TBL] [Abstract][Full Text] [Related]
17. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological targeting of the pseudokinase Her3.
Xie T; Lim SM; Westover KD; Dodge ME; Ercan D; Ficarro SB; Udayakumar D; Gurbani D; Tae HS; Riddle SM; Sim T; Marto JA; Jänne PA; Crews CM; Gray NS
Nat Chem Biol; 2014 Dec; 10(12):1006-12. PubMed ID: 25326665
[TBL] [Abstract][Full Text] [Related]
19. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
20. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
Awasthi S; Ezelle H; Hassel BA; Hamburger AW
Mol Cell Biochem; 2015 Jul; 405(1-2):177-86. PubMed ID: 25876877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
